[BioUSA] 'Customer Friendly' Samba Secures Bases on Both East and West Coasts of the US

Kevin Sharp, US Sales Executive
"Working Hours Aligned with Clients, Real-Time Communication"

Samsung Biologics has firmly established strong bases on both the East and West Coasts of the United States by building a sales office in New Jersey following its research and development (R&D) center in San Francisco on the West Coast. Through this, the company aims to secure a super-gap as a 'customer-friendly' partner by communicating in real-time with major clients located in the US and Europe.

Kevin Sharp, an executive in charge of sales at Samsung Biologics in the United States, is speaking at a press conference held on the 6th (local time) at the Boston Convention & Exhibition Center in the United States.
[Photo by Lee Chunhee]

Kevin Sharp, Executive Director in charge of sales at Samsung Biologics USA, cited continuous contact with clients as the greatest advantage gained through the New Jersey office during a press briefing held on the 6th (local time) at the Boston Convention & Exhibition Center in the US, where the BIO International Convention (BIO USA) is taking place. Sharp explained, “The New Jersey office will operate during the clients’ business hours and communicate in real-time,” adding, “Through client-centered activities, we plan to simultaneously operate the headquarters in Songdo and the sales office to provide not only manufacturing but also one-stop services locally.”

Since establishing the sales office in New Jersey in March last year, Samsung Biologics has been achieving remarkable results in sales. During this BIO USA period, the company revealed that it successfully increased the number of clients among the global top 20 big pharma companies from 12 to 13. Among the major disclosed clients are AstraZeneca, GlaxoSmithKline (GSK), Moderna, Janssen, Eli Lilly, Roche, Bristol Myers-Squibb (BMS), Gilead, Merck (MSD) in the US, and Pfizer. Sharp stated, “We plan to closely collaborate with seven potential clients as well,” adding, “Some are currently in active discussions, and although it is difficult to specify, we expect to expand our client base in the near future.”

Through these efforts, Samsung Biologics recently achieved a milestone of surpassing $10 billion (approximately 13 trillion KRW) in cumulative orders since its founding in 2011. Sharp explained, “Samsung Biologics’ cumulative orders have grown significantly over the past five years,” adding, “Especially, the growth was possible as the 4th plant was filled with new products.”

Exterior view of Samsung Biologics' sales office in New Jersey, USA [Photo by Samsung Biologics]

This achievement demonstrates that the opening of the New Jersey sales office was a highly effective strategy. Sharp said, “The New Jersey office will focus not only on existing core clients but also on new clients,” adding, “We will communicate with clients in the US and Europe locally and expand this base.”

Regarding the possibility of new geographic expansions such as a European office, he said, “The headquarters of big pharma companies are mostly located in the US and Europe, and decision-makers are largely concentrated on the US East Coast,” adding, “That is why we established the New Jersey office, and we are currently reviewing options in Europe as well.” Earlier, CEO John Rim also emphasized the regional advantage of New Jersey, stating, “Global pharmaceutical companies are concentrated on the US East Coast and Europe,” and “European pharmaceutical companies also have many branches on the US East Coast.”